These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18847413)

  • 21. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanthanum carbonate.
    Joy MS; Kshirsagar A; Candiani C; Brooks T; Hudson JQ
    Ann Pharmacother; 2006 Feb; 40(2):234-40. PubMed ID: 16449551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental advances in mineral metabolism].
    Valdivieso JM
    Nefrologia; 2008; 28 Suppl 5():47-50. PubMed ID: 18847420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
    Damment SJ; Pennick M
    Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
    Joki N
    Clin Calcium; 2009 Feb; 19(2):213-8. PubMed ID: 19182361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
    Okabe T; Katoh M; Kano M; Okazaki R; Tanaka Y; Toyoda H; Ueno M
    Yakugaku Zasshi; 2019; 139(11):1435-1448. PubMed ID: 31685740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lanthanum: a safe phosphate binder.
    Persy VP; Behets GJ; Bervoets AR; De Broe ME; D'Haese PC
    Semin Dial; 2006; 19(3):195-9. PubMed ID: 16689967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
    Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
    Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
    J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
    Bervoets AR; Behets GJ; Schryvers D; Roels F; Yang Z; Verberckmoes SC; Damment SJ; Dauwe S; Mubiana VK; Blust R; De Broe ME; D'Haese PC
    Kidney Int; 2009 Feb; 75(4):389-98. PubMed ID: 19052535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progressive accumulation of lanthanum in the liver of normal and uremic rats.
    Slatopolsky E; Liapis H; Finch J
    Kidney Int; 2005 Dec; 68(6):2809-13. PubMed ID: 16316357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
    Behets GJ; Verberckmoes SC; Oste L; Bervoets AR; Salomé M; Cox AG; Denton J; De Broe ME; D'Haese PC
    Kidney Int; 2005 May; 67(5):1830-6. PubMed ID: 15840030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.
    Chan MR; Yevzlin AS; Hinshaw M; Jaffery JB
    WMJ; 2008 Nov; 107(7):335-8. PubMed ID: 19180873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
    Yajima A; Inaba M; Tominaga Y; Tanaka M; Otsubo S; Nitta K; Ito A; Satoh S
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():41-8. PubMed ID: 23586512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
    Tatsuta K; Shigematsu T
    Clin Calcium; 2009 Feb; 19(2):219-23. PubMed ID: 19182362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
    Damment S; Secker R; Shen V; Lorenzo V; Rodriguez M
    Nephrol Dial Transplant; 2011 Jun; 26(6):1803-12. PubMed ID: 21098011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.